Neutrophil CD64 is upregulated in RA patients with lymphoma but not in other solid cancers

References

• Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961;40:1–30.
   PubMed Web of Science ®Google Scholar
• de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore). 1997;76(6):392–400.
   PubMed Web of Science ®Google Scholar
• Mourad O, Palda V, Detsky AS. A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med. 2003;163(5):545–51.
   PubMed Web of Science ®Google Scholar
• Leino L, Sorvajärvi K, Katajisto J, Laine M, Lilius EM, Pelliniemi TT, et al. Febrile infection changes the expression of IgG Fc receptors and complement receptors in human neutrophils in vivo. Clin Exp Immunol 1997;107(1):37–43.
   PubMed Web of Science ®Google Scholar
• Fjaertoft G, Hakansson L, Ewald U, Foucard T, Venge P. Neutrophils from term and preterm newborn infants express the high-affinity Fc gamma-receptor I (CD64) during bacterial infections. Pediatr Res 1999;45(6):871–6.
   PubMed Web of Science ®Google Scholar
• Ng PC, Li K, Wong RP, Chui KM, Wong E, Fok TF. Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants. Pediatr Res 2002;51(3):296–303.
   PubMed Web of Science ®Google Scholar
• Layseca-Espinosa E, Pérez-González LF, Torres-Montes A, Baranda L, de la Fuente H, Rosenstein Y, González-Amaro R. Expression of CD64 as a potential marker of neonatal sepsis. Pediatr Allergy Immunol. 2002;13(5):319–27.
   PubMed Web of Science ®Google Scholar
• Buckle AM, Hogg N. The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol. 1989;143(7):2295–301.
   PubMed Web of Science ®Google Scholar
• Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach IC, Kleijer M, von dem Borne AE, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood. 1993;82(11):3265–72.
   PubMed Web of Science ®Google Scholar
• Matsui T, Ohsumi K, Ozawa N, Shimada K, Sumitomo S, Shimane K, et al. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol. 2006;33(12):2416–24.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14(6):1943–9.
   PubMed Web of Science ®Google Scholar
• Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26(6):794–804.
   PubMed Web of Science ®Google Scholar
• Sibilia J, Lioté F, Mariette X. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998;65(4):267–73.
   PubMedGoogle Scholar
• Yoshida Y, Takahashi Y, Yamashita H, Kano T, Kaneko H, Mimori A. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014;24(5):763–5.
   PubMed Web of Science ®Google Scholar
• Mokuda S, Miyazaki T, Saeki Y, Masumoto J, Kanno M, Takasugi K. Epstein-Barr virus-related MTX-LPD in rheumatoid arthritis patients exhibits a viral pattern of the CD64 and CD35 expression on neutrophils: three case reports. Mod Rheumatol. 2015;25(1):166–8.
   PubMed Web of Science ®Google Scholar
• Dovsak T, Ihan A, Didanovic V, Kansky A, Ihan Hren N. Influence of surgical treatment and radiotherapy of the advanced intraoral cancers on complete blood count, body mass index, liver enzymes and leukocyte CD64 expression. Radiol Oncol. 2009;43(4):282–92.
   Web of Science ®Google Scholar
• van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2011;63(1):37–42.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344–7.
   PubMed Web of Science ®Google Scholar
• Bird HA, Esselinckx W, Dixon ASTJ, Mowat AF, Wood PHN. An evaluation of criteria for polymyalgia rheuatica. Ann Rheum Dis. 1979;38(5):434–9.
   PubMed Web of Science ®Google Scholar
• Komiya A, Matsui T, Nogi S, Iwata K, Futami H, Takaoka H, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still's disease. Scand J Rheumatol. 2012;41(2):156–8.
   PubMed Web of Science ®Google Scholar
• Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol. 2009;19(6):696–7.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–71.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82(12):1106–9.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–8.
   PubMed Web of Science ®Google Scholar
• Hsu SM, Hsu PL. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed Pharmacother. 1994;48(10):433–44.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283–97.
   PubMed Web of Science ®Google Scholar
• Blay JY, Farcet JP, Lavaud A, Radoux D, Chouaïb S. Serum concentrations of cytokines in patients with Hodgkin's disease. Eur J Cancer. 1994;30A(3):321–4.
   PubMed Web of Science ®Google Scholar
• Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19(24):6812–19.
   PubMed Web of Science ®Google Scholar
• Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res. 1997;3(12 Pt 2):2581–4.
   PubMed Web of Science ®Google Scholar
• Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82(7):2169–74.
   PubMed Web of Science ®Google Scholar
• Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56(23):5499–505.
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine. 2012;60(3):882–9.
   PubMed Web of Science ®Google Scholar
• Lichtenfeld JL, Wiernik PH, Mardiney MR Jr, Zarco RM. Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma. Cancer Res. 1976;36(10):3678–80.
   PubMed Web of Science ®Google Scholar
• Heier HE, Carpentier NA, Lambert PH, Godal T. Quantitation of serum complement components and plasma C3d in patients with malignant lymphoma: relation to the stage of the tumor and circulating immune complexes. Int J Cancer. 1978;21(6):695–9.
   PubMed Web of Science ®Google Scholar